MicroRNA-mediated high expression of PDIA3 was correlated with poor prognosis of patients with LUAD

• Published in: Genomics (San Diego, Calif.) Calif.), 2022-07, Vol.114 (4), p.110417-110417, Article 110417
• Main Authors: Gu, Xue, Li, Xiaoli, Zhang, Xue, Feng, Ran, Zheng, Miaosen, Liu, Lei, Yang, Juanjuan, Sun, Hui, Zhang, Qing, Bian, Tingting, Zhao, Hongyu, Liu, Yifei
• Format: Article
• Language: English
• Subjects: adenocarcinoma; biomarkers; gene expression; gene expression regulation; genomics; immunotherapy; LUAD; lung neoplasms; lungs; miR-301a-5p; PD-1/PD-L1; PDIA3; prognosis; protein synthesis
• ISSN: 0888-7543; 1089-8646
• DOI: 10.1016/j.ygeno.2022.110417

Lung cancer, especially lung adenocarcinoma (LUAD) as the most common subtype has threatened the health of people. Even though more and more patients diagnosed as LUAD could be treated efficiently or even cured, a spilt of patients still suffer from disease. Here, on the basis of previous research, we firstly performed the mRNA expression of PDIA3 in pan-cancer, and differential expression between tumor and normal groups was followed. We further analyzed the survival difference and ultimately the expression of PDIA3 in LUAD was selected as our current study. Next, we investigated the mRNA and protein expression of PDIA3 from online databases and performed qRT-PCR and western blotting to verify the outcomes. We still analyzed the correlation between the expression of PDIA3 and clinicopathologic parameters and predicted the potential signal pathways as well as the possible upstream molecular of PDIA3. Considering the correlation of PDIA3 and immune infiltration, related analysis of PDIA3 and immune biomarkers along with PD-1/PD-L1, CTLA-4 were made. We clarified the expression of PDIA3 was upregulated in LUAD and its oncogenic role may be played through tumor infiltration. Thus targeting PDIA3 and immune checkpoint could enhance the efficacy of immunotherapy on patients with LUAD. •Lung cancer, especially lung adenocarcinoma (LUAD) as the most common subtype has threatened the health of people.•Even though more and more patients diagnosed as LUAD could be treated efficiently or even cured, a spilt of patients still suffer from disease.•Here, on the basis of previous research, we firstly performed the mRNA expression of PDIA3 in pan-cancer, and differential expression between tumor and normal groups was followed.•We further analyzed the survival difference and ultimately the expression of PDIA3 in LUAD was selected as our current study.•Next, we investigated the mRNA from online datasets and performed qRT-PCR to verify the outcomes.•We also analyzed the protein expression of PDIA3 by western blotting and IHC.•We still analyzed the correlation between the expression of PDIA3 and clinicopathologic parameters and predicted the potential signal pathways as well as the possible upstream molecular of PDIA3.•Considering the correlation of PDIA3 and immune infiltration, related analysis of PDIA3 and immune biomarkers along with PD-1/PD-L1, CTLA-4 were made.•We clarified the expression of PDIA3 was upregulated in LUAD and its oncogenic role may be played through tumor